{
  "abstract": "End-stage renal disease (ESRD) on hemodialysis (HD) require EPO for anemia complication. Oxalate increases halts Vit C use. This study assessed the safety and efficacy of oral Vit C in reducing erythropoietin (EPO) requirements in patients with HD. This randomized, open-label trial included 60 ESRD patients on stable HD (≥ 90 days) with hemoglobin (Hgb) 9–11 g/dL, transferrin saturation (TSAT) < 30%, ferritin > 100 µg/L, and stable EPO dose for two months. Patients were randomly assigned to one of three groups: A, control-standard regimen; B, standard regimen plus 250 mg/day Vit C, and C, standard regimen plus 500 mg/day Vit C, all for three months. Monthly assessments included Hgb, serum iron (Fe), TSAT, total iron-binding capacity (TIBC), EPO dose, and serum oxalate. Safety was monitored through oxalate measurements. Vit C groups (B and C) demonstrated significant increases in Hgb, serum Fe, and TSAT, along with significant reductions in TIBC and EPO dose versus group (A), (P < 0.05). The percentage reduction in EPO doses at two and three months was comparable and significant in both the Vit C groups. Serum ferritin decreased over time in the Vit C groups and decreased in the control. Serum oxalate increased significantly in both Vit C groups, with higher levels observed in the 500 mg-group. Oral Vit C in ESRD patients on HD improved Fe use and lowered EPO needed short term. Both Vit C 250 mg and 500 mg were effective, but 500 mg increased oxalates more.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "name": "Marwa El-banna",
      "orcid": "0009-0004-0450-1424"
    },
    {
      "name": "Tamer ElSaid",
      "orcid": "0000-0002-3458-1734"
    },
    {
      "name": "Radwa Maher Elborolossy",
      "orcid": "0000-0003-3868-7832"
    },
    {
      "name": "Lamia Mohamed El Wakeel",
      "orcid": "0000-0003-0250-1709"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/5qkj4yw94pkz8.bib",
  "cited_by": 0,
  "doi": "10.1038/s41598-026-73671-9",
  "fulltext_url": "https://doi.org/10.1038/s41598-026-73671-9",
  "id": "5qkj4yw94pkz8",
  "issns": [
    "2045-2322"
  ],
  "landing_url": "https://www.nature.com/articles/s41598-026-73671-9",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "Q"
    ],
    [
      "lcc",
      "R"
    ]
  ],
  "openalex": null,
  "pdf_url": "https://www.nature.com/articles/s41598-026-73671-9.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-02",
  "publisher": "Springer Science and Business Media LLC",
  "ris": "https://research.draconitic.com/paper/5qkj4yw94pkz8.ris",
  "sources": [
    {
      "first_seen": "2026-11-02T12:20:45Z",
      "native_id": "10.1038/s41598-026-73671-9",
      "source": "crossref",
      "url": "https://www.nature.com/articles/s41598-026-73671-9"
    },
    {
      "first_seen": "2026-11-08T14:20:57Z",
      "native_id": "018b25892faa47d9bd22950ad6012314",
      "source": "doaj",
      "url": "https://doi.org/10.1038/s41598-026-73671-9"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "lcc:R",
      "subfield": "general"
    }
  ],
  "title": "The safety and efficacy of oral vitamin C administration on erythropoietin dosing requirements in end stage renal disease patients on regular hemodialysis",
  "title_text": "The safety and efficacy of oral vitamin C administration on erythropoietin dosing requirements in end stage renal disease patients on regular hemodialysis",
  "type": "peer-reviewed",
  "updated_at": "2026-11-09T14:21:17Z",
  "url": "https://research.draconitic.com/paper/5qkj4yw94pkz8",
  "venue": "Scientific Reports",
  "versions": []
}